CG 0255
Alternative Names: CG-0255Latest Information Update: 28 Oct 2024
At a glance
- Originator Shanghai CureGene Pharmaceutical
- Class Antiplatelets; Cardiovascular therapies
- Mechanism of Action Purinoceptor P2Y12 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cardiovascular disorders
Most Recent Events
- 30 Aug 2024 Updated pharmacodynamics data from a phase I trial in Cardiovascular disorders presented at the Annual Congress of the European Society of Cardiology (ESC-2024)
- 05 Dec 2023 Shanghai CureGene Pharmaceutical has patent protection for CG 0255 in USA
- 11 Nov 2023 Phase-I clinical trials in Cardiovascular disorders (In volunteers) (IV), prior to November 2023